Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
PONTE VEDRA, Fla. - Treace Medical Concepts, Inc. (NASDAQ:TMCI), a medical technology company specializing in the surgical treatment of bunions, has filed a lawsuit against Zimmer Biomet Holdings, Inc. (NYSE:ZBH), a medical device company with $7.7 billion in annual revenue and a market capitalization of $18.3 billion, and Paragon 28, Inc., alleging patent infringement. The lawsuit, submitted to the United States District Court for the District of Delaware, cites infringement of four patents related to Treace’s Lapiplasty® 3D Bunion Correction® technologies.
The company is seeking injunctive relief and damages, asserting the necessity of the legal action to protect its investments in its patented technologies. John T. Treace, Chairman, CEO, and Founder of Treace, emphasized the importance of defending their intellectual property to sustain innovation that benefits patients and stockholders. Treace Medical’s patent portfolio boasts 80 granted U.S. patents, 26 international patents, and over 150 pending patent applications. According to InvestingPro analysis, Zimmer Biomet maintains a strong financial health rating and is currently trading below its Fair Value, with liquid assets exceeding short-term obligations.
The Lapiplasty® 3D Bunion Correction® System, Treace Medical’s flagship product, represents a significant advancement in the treatment of bunions, a common foot deformity affecting an estimated 67 million Americans. For deeper insights into Zimmer Biomet’s market position and financial metrics, including additional ProTips and comprehensive analysis, visit InvestingPro, where you’ll find detailed research reports covering 1,400+ top stocks. The system aims to correct the deformity in all three planes and stabilize the joint at the root cause. In addition to Lapiplasty®, Treace has developed the Adductoplasty® Midfoot Correction System, the SpeedMTP™ Rapid Compression Implant, the Nanoplasty™ 3D Minimally Invasive Bunion Correction System, and the Percuplasty™ Percutaneous 3D Bunion Correction System.
The company continues to innovate within the foot and ankle market, also introducing the SpeedPlate™ Rapid Compression Implants, designed for use in various bone fusion procedures, including Lapiplasty® and Adductoplasty® surgeries. Zimmer Biomet maintains a strong position in this market, with a gross profit margin of 71.2% and consistent dividend payments maintained for 14 consecutive years.
The information in this article is based on a press release statement from Treace Medical Concepts, Inc.
In other recent news, Zimmer Biomet Holdings, Inc. reported its first-quarter financial results, revealing sales of $1.91 billion, which marked a 2.3% growth on a constant currency basis and slightly exceeded Wall Street’s expectations by $14 million. The company also achieved an adjusted earnings per share (EPS) of $1.81, surpassing the consensus by 2.5%. In addition to financial updates, Zimmer Biomet announced amendments to its 2009 Stock Incentive Plan, which include an increase in shares available for issuance and the inclusion of independent contractors in the plan. Shareholders have also approved amendments to the company’s Restated Certificate of Incorporation, limiting the personal liability of certain officers for monetary damages related to breaches of the duty of care.
Analyst firms have adjusted their price targets for Zimmer Biomet, with Bernstein SocGen lowering the target from $105 to $100, while maintaining a Market Perform rating, citing concerns about the company’s outlook for the second half of the year and potential tariff impacts. Similarly, TD Cowen reduced its price target from $119 to $104, maintaining a Hold rating, due to uncertainties surrounding tariffs and the company’s future guidance. Zimmer Biomet has also declared a quarterly dividend of $0.24 per share, payable on July 31, 2025, to stockholders of record as of June 26, 2025. Additionally, the company announced the appointment of Kevin Thornal as the Group President of Global Businesses and the Americas, effective July 1, 2025, to lead business strategy and execution.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.